Oncology Medical News about HPV-induced oropharyngeal cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

HPV-induced oropharyngeal cancer, immune response and response to therapy
Cancer Letters, 08/18/09

Vu HL et al. - In a review of human papillomaviruses (HPV)-induced oropharyngeal cancer and the immune response and response to therapy, this article outlines several mechanisms whereby the observed improved response of HPV-positive tumors to radiotherapy may be related to enhancement of immune response following radiotherapy.

Methods

Approximately 25% of head and neck squamous cell carcinoma (HNSCC) worldwide are associated with high-risk HPV.
HPV-positive HNSCCs have a more favorable outcome and greater response to therapy.

Results

While chronic HPV infection allows for the evolution of immune evasion mechanisms, viral antigens can still elicit an immune response.
A robust lymphocytic response is associated with better prognosis in a variety of tumor types including head and neck cancer.

<< Previous
Melatonin sensitizes human malignant glioma cells against...

Next >>
Novel treatments for hepatocellular cancer